Trial Profile
A Study to comparison of fingolimod and dimethyl fumarate in patients with multiple sclerosis in real world
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2017
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary) ; Fingolimod (Primary) ; Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 28 Apr 2017 Results (n=789) comparing data for fingolimod versus dimethyl fumarate, through addition of natalizumab as the third arm, presented at the 69th Annual Meeting of the American Academy of Neurology
- 20 Nov 2016 New trial record